You are here

  • Home
  • Archive
  • Volume 80, Issue 3
  • Efficacy and safety of abatacept in active primary Sjögren’s syndrome: results of a phase III, randomised, placebo-controlled trial

Article metrics

Article menu
XML
Sjögren’s syndrome
Efficacy and safety of abatacept in active primary Sjögren’s syndrome: results of a phase III, randomised, placebo-controlled trial

 

Online download statistics by month:

Online download statistics by month: November 2020 to August 2023

AbstractFullPdf
Nov 2020939912406
Dec 2020411407152
Jan 2021197194105
Feb 202123712370212
Mar 202114401430168
Apr 202128527947
May 202121320874
Jun 202118518264
Jul 202121120671
Aug 202117917562
Sep 202114113652
Oct 202117617179
Nov 2021176176115
Dec 202113212275
Jan 202217417265
Feb 202214714561
Mar 202215916355
Apr 202217416643
May 202214914942
Jun 202215214948
Jul 202211610635
Aug 202214013872
Sep 202226826482
Oct 202217717298
Nov 202218517354
Dec 202213612658
Jan 202312412140
Feb 202317116163
Mar 202321821770
Apr 202316215150
May 202315013568
Jun 202317512655
Jul 202312711275
Aug 202310410233
Total10264100162849